论文部分内容阅读
目的 研究正常人细胞因子激活的杀伤细胞 (Cytokine inducedkiller,CIK)对人胃癌细胞株OCUM 2MD3的体外细胞毒活性以及对胃癌腹膜移植模型的体内抗肿瘤作用。方法 取正常人外周血单个核细胞 (Peripheralbloodmononuclearcell,PBMC) ,加入γ IFN、IL 2、抗 CD3单抗和IL 1,体外诱导成CIK细胞 ,用流式细胞仪对细胞作动态表型分析 ,用MTT法测定CIK细胞体外对OCUM 2MD3的细胞毒活性 ,并与CD3AK作对比。在Balb/c裸小鼠腹腔内接种OCUM 2MD3细胞 ,观察CIK细胞对荷瘤鼠的抑瘤作用。结果 CIK细胞在培养 2周左右获得大量增殖 ,CD3+ CD5 6 + 双阳性细胞大量增殖达 10 0 0倍以上 ;体外实验证明 ,CIK细胞对OCUM 2MD3有明显的细胞毒活性 ,对比CD3AK其抑瘤率为 85 %与 6 2 .8% (P <0 .0 5 )。体内实验表明 ,CIK细胞能够显著抑制癌性腹水的生长 ,其抑瘤率可达 10 0 % ;肿瘤标志物CEA含量明显降低。结论 CIK细胞是一种新型、高效的免疫活性细胞 ,具有较强的体内外抗胃癌细胞活性 ,具有明显的抑制癌性腹水的生长的作用 ,有可能用于临床上晚期胃癌的过继性免疫治疗
Objective To study the cytotoxicity of normal human cytokine-activated killer (CIK) on human gastric cancer cell line OCUM 2MD3 in vitro and the antitumor effect in vivo on the model of peritoneal transplantation of gastric cancer. Methods Peripheral blood mononuclear cells (PBMCs) were obtained from human peripheral blood mononuclear cells (PBMCs). IFNα, IL-2, anti-CD3 monoclonal antibodies and IL-1 were added into CIK cells. CIK cells were induced by flow cytometry. The cytotoxic activity of CIK cells against OCUM 2MD3 was measured by MTT assay and compared with that of CD3AK. OCUM 2MD3 cells were inoculated intraperitoneally in Balb / c nude mice to observe the antitumor effect of CIK cells on tumor-bearing mice. Results CIK cells proliferated significantly after culturing for about 2 weeks, and large numbers of CD3 + CD5 6 + double positive cells proliferated by more than 100 times. In vitro experiments showed that CIK cells had obvious cytotoxic activity against OCUM 2MD3, compared with that of CD3AK Was 85% and 62.8% (P <0.05). In vivo experiments show that, CIK cells can significantly inhibit the growth of cancerous ascites, the inhibition rate of up to 10%; CEA content of tumor markers was significantly reduced. Conclusions CIK cells are a new type of highly effective immunocompetent cells with strong anti-gastric cancer cell activity in vitro and in vivo. They have significant inhibitory effects on the growth of cancerous ascites and may be used in adoptive immunotherapy of advanced gastric cancer